Image

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Recruiting
22-65 years
Male
Phase 4

Powered by AI

Overview

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Description

Male subject diagnosed with a stricture in the anterior urethra that can be treated with the Optilume Urethral DCB. Thirty-Four (34) subjects will be enrolled at up to ten (10) sites in the United States. Clinical follow-up will be conducted at 30 days, 3 months, 6 months, and 12 months post-treatment evaluating Lower Urinary Tract Symptoms (LUTS), sexual function, and voiding function. Semen quality parameters will be assessed at Baseline, 3 months, and 6 months post-treatment. Subjects with an abnormal semen quality result at 6 months will have an additional assessment at 12 months post-treatment and periodically thereafter until results return to normal.

Eligibility

Inclusion Criteria:

  1. Male subjects between 22 and 65 years of age
  2. Subject diagnosed with a stricture in the anterior urethra that is able to be treated with the Optilume Urethral DCB in accordance with the approved Instructions for Use
  3. Subject is willing to provide written informed consent and comply with study required follow-up assessments
  4. Subject able to provide viable semen samples and baseline semen quality characteristics are above reference values based on below criteria (average of 2 samples):
    1. total sperm ≥39 million
    2. sperm concentration ≥15 million/mL
    3. total motility ≥40%
    4. progressive motility ≥32%
    5. morphology ≥4%

Exclusion Criteria:

  1. Subjects with a known hypersensitivity to paclitaxel or structurally related compounds
  2. Subjects with a history of vasectomy or other condition that may inhibit semen/sperm production or ejaculatory function
  3. Subjects currently taking 5-alpha reductase inhibitors, alpha-blockers, selective serotonin reuptake inhibitors, or hormone replacement therapy without appropriate washout
  4. Subject is unwilling to abstain or utilize a condom for 30 days after the procedure
  5. Subject is unwilling to utilize highly effective contraception for 6 months after the procedure if partner is of childbearing potential
  6. History of cancer in any body system that is not considered in complete remission

Study details
    Urethral Stricture

NCT05383274

Urotronic Inc.

14 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.